# Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data

> **NCT03078049** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 11971 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03078049
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-31
- **Primary completion:** 2017-04-30
- **Final completion:** 2017-05-31
- **Target enrollment:** 11971 (ACTUAL)
- **Last updated:** 2018-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03078049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03078049, "Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03078049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*